How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

3,717 results for

Thromboembolic Disease in Pregnancy

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

61. Guidelines for Weight Gain During Pregnancy: A Focused Practice Question

be gained during pregnancy. The search included: Turning Research into Practice (TRIP) database, National Guideline Clearinghouse, National Institute for Health Care Excellence (NICE), Society of Obstetricians and Gynaecologists of Canada (SOGC), Health Canada, Public Health Agency of Canada, Public Health Ontario, Centers for Disease Control and Prevention (CDC), Institute of Medicine, and the World Health Organization. The search was completed in November 2015 and is outlined in Appendix A. 4 (...) dystocia, caesarean section and thromboembolism. Refer to the data extraction table in Appendix C for further information regarding the SOGC guideline. 7 8. Synthesis of Findings ? The recommended amount of weight that a woman gains during her pregnancy is a range that is based on her pre-pregnancy body mass index (BMI). ? For women with a normal weight, 11.5 - 16 kg (25-35 lbs) is the recommended weight gain during pregnancy. ? These ranges are applicable to all women with singleton pregnancies

2016 Peel Health Library

62. Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer

Posted : October 26, 2018 See Sponsor: Fadoi Foundation, Italy Collaborator: University of Perugia, Italy Information provided by (Responsible Party): Fadoi Foundation, Italy Study Details Study Description Go to Brief Summary: Apixaban for the treatment of venous thromboembolism in patients with cancer: a prospective randomized open blinded end-point (PROBE) study Condition or disease Intervention/treatment Phase Venous Thromboembolism Drug: Apixaban Drug: Dalteparin Phase 3 Study Design Go (...) Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more

2017 Clinical Trials

63. Thrombosis Outcomes in Pediatric Venous Thromboembolism

biomarkers in children that develop poor VTE outcomes (such as recurrence, postthrombotic syndrome and post PE impairment ) after an initial VTE with those that do not develop such outcomes. Condition or disease Venous Thromboembolism Detailed Description: All newly diagnosed patients with a first radiologically confirmed thrombotic event (any site) diagnosed at Children's Medical Center, Dallas will be followed prospectively with global coagulation assessment over a 24-month period, and monitored (...) malignancy Pregnancy or immediate post-partum period (12 weeks after delivery) Sickle cell disease Known bleeding disorder Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03068923 Contacts Layout table for location contacts Contact: Kendra Malone, MPH

2017 Clinical Trials

64. Prophylaxis of Venous Thromboembolism in Advanced Lung Cancer (PROVE)

lung cancer and elevated D-dimer. Condition or disease Intervention/treatment Phase Venous Thromboembolism Lung Neoplasm Drug: Tinzaparin Sodium Phase 3 Detailed Description: Adult patients aged ≥ 18 years with stage IV lung cancer and elevated D-dimer will be randomized to the experimental or control group.Patients in the control group will receive usual care, patients in the experimental group will receive subcutaneous tinzaparin once daily for six months. Follow-up visit will take place (...) table for additional information Studies a U.S. FDA-regulated Drug Product: No Studies a U.S. FDA-regulated Device Product: No Keywords provided by Assistance Publique - Hôpitaux de Paris: Low-molecular-weight Heparin Tinzaparin Additional relevant MeSH terms: Layout table for MeSH terms Thromboembolism Venous Thromboembolism Lung Neoplasms Embolism and Thrombosis Vascular Diseases Cardiovascular Diseases Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Neoplasms Lung Diseases

2017 Clinical Trials

65. REduced Dose Versus Full-dose of Direct Oral Anticoagulant After uNprOvoked Venous thromboEmbolism.

, a reduced dose of DOAC will be non-inferior to a full dose of DOAC in terms of recurrent VTE during extended anticoagulation phase. Condition or disease Intervention/treatment Phase Venous Thromboembolism Drug: Reduced dose of DOAC Drug: Full dose of DOAC Phase 3 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 2200 participants Allocation: Randomized Intervention Model: Parallel Assignment Intervention Model Description: The trial (...) anticoagulant-related bleeding Additional relevant MeSH terms: Layout table for MeSH terms Thromboembolism Venous Thromboembolism Embolism and Thrombosis Vascular Diseases Cardiovascular Diseases Rivaroxaban Apixaban Anticoagulants Factor Xa Inhibitors Antithrombins Serine Proteinase Inhibitors Protease Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action

2017 Clinical Trials

66. Distribution of Risk Factors for Venous Thromboembolism in Blood Donors

in the presence of cancer. The risk increases with the age for unclear reasons. There are also differences in the incidence according to ethnicity; however, data in subjects of European ancestry are scarce. Several studies have documented an association between thrombosis and ABO group. Specifically, non-O blood groups have a higher risk of myocardial infarction, angina, peripheral vascular disease, cerebral ischemia and venous thromboembolism than O. While there are numerous studies carried out in patients (...) who have already shown thromboembolic events, data on the incidence of risk factors in the healthy population are completely inadequate. Understanding the risk factors for venous thrombosis is necessary to maximize the prevention of this disease in individuals and groups of high-risk patients . For this purpose a self-administered questionnaire will be used. Data obtained by blood donors on exposure to risk factors will be used to set up a clinical score to validate in future studies to carry out

2017 Clinical Trials

67. Is Infection an Independent Risk Factor for Venous Thromboembolism? a Population-Based Case-Control Study. (PubMed)

/recent hospitalization with/without surgery, nursing home confinement, active cancer, trauma/fracture, leg paresis, prior superficial vein thrombosis, transvenous catheter/pacemaker, ischemic heart disease, congestive heart failure, chronic lung or renal disease, serious liver disease, asthma, diabetes mellitus, hormone therapy, and pregnancy/postpartum.A total of 513 cases (39.4%) and 189 controls (12.7%) had an infection in the previous 92 days (odds ratio, 4.5; 95% confidence interval, 3.6-5.5; P (...) Is Infection an Independent Risk Factor for Venous Thromboembolism? a Population-Based Case-Control Study. The independent association of recent infection with venous thromboembolism is uncertain. The study aims were to test both overall infection (site unspecified) and specific infection sites as potential risk factors for deep vein thrombosis and pulmonary embolism adjusting for other known venous thromboembolism factors.By using Rochester Epidemiology Project resources, we identified all

2017 American Journal of Medicine

68. Epidemiology of venous thromboembolism in Africa: a systematic review. (PubMed)

Epidemiology of venous thromboembolism in Africa: a systematic review. Essentials Venous thromboembolism (VTE) is among the three main causes of cardiovascular disease worldwide. This review is the first to summarize the epidemiology of VTE in African populations. The prevalence of VTE in Africa is high following surgery, in pregnancy and post-partum. At least one quarter of patients at risk of VTE in Africa are not receiving prophylaxis.Background Venous thromboembolism (VTE) is among (...) the three leading causes of cardiovascular disease worldwide. Despite its high burden, there has been no previous study summarizing the epidemiology of VTE in African populations. Hence, we conducted this systematic review to determine the prevalence, incidence and mortality associated with VTE, and to evaluate the use of VTE prophylaxis in Africa. Methods We searched PubMed, Scopus and African Journals Online to identify articles published on VTE in Africa from inception to November 19, 2016, without

Full Text available with Trip Pro

2017 Journal of thrombosis and haemostasis : JTH

69. Incidence and risk factors of venous thromboembolism during postpartum-period: a population-based cohort-study. (PubMed)

, primiparity, cesarean section, cardiac/renal diseases, and varicose veins were associated with an increased risk for postpartum venous thromboembolic events. The risk remained elevated for 180 days in women with thrombophilia, cesarean section, multiple pregnancy, varicose veins, and cardiac disease.The risk of venous thromboembolic events remained elevated compared with that of the nonpregnant women after the usually defined postpartum period (6 weeks). The results might assist in selecting women in need (...) , declining to two-fold immediately after that. Almost half of the venous thromboembolic events occurred between 43 and 180 days postpartum. The incidence of venous thromboembolic events was four-fold compared with that of nonpregnant women. Three venous thromboembolic events-related deaths occurred. Older age, higher body mass index, thrombophilia, multiple pregnancy, gestational diabetes, anemia, chorioamnionitis, threatening premature birth, in vitro fertilization with ovarian hyperstimulation

2017 Acta Obstetricia et Gynecologica Scandinavica

70. Low Molecular Weight Heparin (LMWH) vs Aspirin for Venous Thromboembolism (VTE) Prophylaxis in Orthopaedic Oncology

: 1) soft tissue sarcoma; 2) primary bone sarcoma; 3) metastatic bone disease. Within each of these groups, patients will be randomized to either aspirin or low molecular weight heparin (enoxaparin) for venous thromboembolism prophylaxis post operatively. Masking: None (Open Label) Primary Purpose: Prevention Official Title: Low Molecular Weight Heparin Versus Aspirin for Venous Thromboembolism Prophylaxis in Orthopaedic Oncology Actual Study Start Date : February 16, 2018 Estimated Primary (...) in and Exported from the U.S.: Yes Additional relevant MeSH terms: Layout table for MeSH terms Sarcoma Thromboembolism Venous Thromboembolism Hematoma Osteosarcoma Neoplasms, Connective and Soft Tissue Neoplasms by Histologic Type Neoplasms Embolism and Thrombosis Vascular Diseases Cardiovascular Diseases Hemorrhage Pathologic Processes Neoplasms, Bone Tissue Neoplasms, Connective Tissue Aspirin Heparin Heparin, Low-Molecular-Weight Dalteparin Anti-Inflammatory Agents, Non-Steroidal Analgesics, Non-Narcotic

2017 Clinical Trials

71. Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism

and rivaroxaban for the treatment of VTE. Condition or disease Intervention/treatment Phase Venous Thromboembolism Drug: Apixaban Drug: Rivaroxaban Phase 4 Detailed Description: VTE is the third leading cause of mortality by cardiovascular disease. Standard treatment for acute VTE uses a combination of parenteral Low-Molecular-Weight Heparin (LMWH) and oral vitamin K antagonists (VKA) for 3 months, and carries significant bleeding risk. The major and/or clinically-relevant non-major bleeding (CRNMB) event (...) Data (IPD) Sharing Statement: Plan to Share IPD: Undecided Layout table for additional information Studies a U.S. FDA-regulated Drug Product: No Studies a U.S. FDA-regulated Device Product: No Additional relevant MeSH terms: Layout table for MeSH terms Thromboembolism Venous Thromboembolism Embolism and Thrombosis Vascular Diseases Cardiovascular Diseases Rivaroxaban Apixaban Factor Xa Inhibitors Antithrombins Serine Proteinase Inhibitors Protease Inhibitors Enzyme Inhibitors Molecular Mechanisms

2017 Clinical Trials

72. Registry of Patients With Chronic Thromboembolic Pulmonary Hypertension in Novosibirsk Region

: Recruiting First Posted : November 21, 2017 Last Update Posted : November 21, 2017 See Sponsor: Novosibirsk Scientific Research Institute for Circulatory Pathology Information provided by (Responsible Party): Novosibirsk Scientific Research Institute for Circulatory Pathology Study Details Study Description Go to Brief Summary: There will be assessment of patients after acute pulmonary embolism for the development of CTEPH Condition or disease Intervention/treatment Chronic Thromboembolic Pulmonary (...) Registry of Patients With Chronic Thromboembolic Pulmonary Hypertension in Novosibirsk Region Registry of Patients With Chronic Thromboembolic Pulmonary Hypertension in Novosibirsk Region - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one

2017 Clinical Trials

73. Risk Factors of Venous Thromboembolism in Women During Hormonal Exposure

See Sponsor: University Hospital, Brest Information provided by (Responsible Party): University Hospital, Brest Study Details Study Description Go to Brief Summary: Young women have an increased risk of venous thromboembolism (VTE) during hormonale exposure (estrogen-containing pill or pregnancy). In order to detect women at higher risk of VTE during hormonal exposure, thrombophilia testing is often performed in order to adapt contraception methods and/or to increases thromboprophylaxy during (...) pregnancy. However, such practice is probably not accurate nor discriminent. Indeed, there are evidence that the impact of the familial history of VTE might be stronger than that of detectable inherited thrombophilia. The "FIT-H" study is a cross-sectional study comparing the prevalence of previous venous thromboembolism in first-degree relatives of women (propositi) who had a first episode of venous thromboembolism in association with hormonal exposure with the prevalence of previous venous

2017 Clinical Trials

74. Thromboembolic Disease in Pregnancy

Thromboembolic Disease in Pregnancy Thromboembolic Disease in Pregnancy Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Thromboembolic (...) Disease in Pregnancy Thromboembolic Disease in Pregnancy Aka: Thromboembolic Disease in Pregnancy , Deep Vein Thrombosis in Pregnancy , Deep Venous Thrombosis During Pregnancy , DVT in Pregnancy , DVT Prophylaxis in Pregnancy II. Epidemiology Venous Thrombosis risk: 0.5 to 3 per 1000 pregnancies risk is increased 5 fold in pregnancy DVT occurs equally in all trimesters (but increases with each trimester and especially postpartum) III. Pathophysiology Hypercoagulation in pregnancy Procoagulants

2015 FP Notebook

75. Diagnosis of Pulmonary Embolism During Pregnancy: A Multicenter Prospective Management Outcome Study. (PubMed)

thrombosis found on ultrasonography [n = 7], positive CTPA result [n = 19], and high-probability V/Q scan [n = 2]) and excluded in 367 (clinical probability and negative D-dimer result [n = 46], negative CTPA result [n = 290], normal or low-probability V/Q scan [n = 17], and other reason [n = 14]). Twenty-two women received extended anticoagulation during follow-up, mainly for previous venous thromboembolic disease. The rate of symptomatic venous thromboembolic events was 0.0% (95% CI, 0.0% to 1.0 (...) Diagnosis of Pulmonary Embolism During Pregnancy: A Multicenter Prospective Management Outcome Study. Data on the optimal diagnostic management of pregnant women with suspected pulmonary embolism (PE) are limited, and guidelines provide inconsistent recommendations on use of diagnostic tests.To prospectively validate a diagnostic strategy in pregnant women with suspected PE.Multicenter, multinational, prospective diagnostic management outcome study involving pretest clinical probability

2018 Annals of Internal Medicine

76. Ectopic pregnancy and miscarriage: diagnosis and initial management

Ectopic pregnancy and miscarriage: diagnosis and initial management Ectopic pregnancy and miscarriage: Ectopic pregnancy and miscarriage: diagnosis and initial management diagnosis and initial management Clinical guideline Published: 12 December 2012 nice.org.uk/guidance/cg154 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guideline represent (...) . Nothing in this guideline should be interpreted in a way that would be inconsistent with complying with those duties. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Ectopic pregnancy and miscarriage: diagnosis and initial management (CG154) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk

2012 National Institute for Health and Clinical Excellence - Clinical Guidelines

77. Management of systemic lupus erythematosus during pregnancy: challenges and solutions (PubMed)

Management of systemic lupus erythematosus during pregnancy: challenges and solutions Systemic lupus erythematosus (SLE) is a chronic, multisystem autoimmune disease predominantly affecting women, particularly those of childbearing age. SLE provides challenges in the prepregnancy, antenatal, intrapartum, and postpartum periods for these women, and for the medical, obstetric, and midwifery teams who provide their care. As with many medical conditions in pregnancy, the best maternal and fetal (...) -neonatal outcomes are obtained with a planned pregnancy and a cohesive multidisciplinary approach. Effective prepregnancy risk assessment and counseling includes exploration of factors for poor pregnancy outcome, discussion of risks, and appropriate planning for pregnancy, with consideration of discussion of relative contraindications to pregnancy. In pregnancy, early referral for hospital-coordinated care, involvement of obstetricians and rheumatologists (and other specialists as required

Full Text available with Trip Pro

2017 Open access rheumatology : research and reviews

78. Reducing the Risk - Thrombosis and Embolism during Pregnancy and the Puerperium

Reducing the Risk - Thrombosis and Embolism during Pregnancy and the Puerperium Reducing the Risk of V enous Thromboembolism during Pregnancy and the Puerperium Green-top Guideline No. 37a April 2015RCOG Green-top Guideline No. 37a © Royal College of Obstetricians and Gynaecologists 2 of 40 Reducing the Risk of Venous Thromboembolism during Pregnancy and the Puerperium This is the third edition of this guideline, first published in 2004 under the title ‘Thromboprophylaxis during Pregnancy (...) , Labour and after Vaginal Delivery’ and revised in 2009 under the title ‘Reducing the Risk of Thrombosis and Embolism during Pregnancy and the Puerperium’. Executive summary of recommendations Prepregnancy and antenatal risk assessment What are the risk factors for venous thromboembolism (VTE) in pregnancy and the puerperium and what is the magnitude of risk for these factors? All women should undergo a documented assessment of risk factors for VTE in early pregnancy or prepregnancy. Risk assessment

2015 Royal College of Obstetricians and Gynaecologists

79. The Acute Management of Thrombosis and Embolism during Pregnancy and the Puerperium

The Acute Management of Thrombosis and Embolism during Pregnancy and the Puerperium Thromboembolic Disease in Pregnancy and the Puerperium: Acute Management Green-top Guideline No. 37b April 2015RCOG Green-top Guideline No. 37b © Royal College of Obstetricians and Gynaecologists 2 of 32 Thromboembolic Disease in Pregnancy and the Puerperium: Acute Management This is the third edition of this guideline. The first edition was published in April 2001 under the same title (numbered Green-top (...) Guideline No. 28) and the second edition was published in February 2007 and reviewed in 2010. Thromboprophylaxis during pregnancy and the puerperium is addressed in Green-top Guideline No. 37a. Executive summary of recommendations Diagnosis of acute venous thromboembolism (VTE) How is acute VTE diagnosed in pregnancy? Any woman with symptoms and/or signs suggestive of VTE should have objective testing performed expeditiously and treatment with low-molecular-weight heparin (LMWH) given (see section 6

2015 Royal College of Obstetricians and Gynaecologists

80. Thrombophilia Testing for Early Pregnancy Loss

Thrombophilia Testing for Early Pregnancy Loss Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed. Rapid responses should be considered along with other (...) not be copied, posted on a web site, redistributed by email or stored on an electronic system without the prior written permission of CADTH or applicable copyright owner. Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners’ own terms and conditions. TITLE: Thrombophilia Testing for Early Pregnancy Loss: Clinical Effectiveness

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>